Bone Marker Changes With Teriparatide/Postmenopausal Osteoporosis
Status:
Completed
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
To test the hypothesis that Teriparatide injections given 20 micrograms/daily subcutaneously,
for one month, are able to produce reliable changes in the bone marker in a severe
osteoporotic population